UUDA Stock Overview
Syntara Limited operates as a clinical stage drug development company that focuses on blood-related cancers.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Syntara Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.009 |
| 52 Week High | AU$0.031 |
| 52 Week Low | AU$0.008 |
| Beta | 0.54 |
| 1 Month Change | -25.00% |
| 3 Month Change | -5.26% |
| 1 Year Change | -68.97% |
| 3 Year Change | -82.00% |
| 5 Year Change | -94.44% |
| Change since IPO | -98.71% |
Recent News & Updates
Recent updates
Shareholder Returns
| UUDA | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -5.3% | 3.2% | 1.7% |
| 1Y | -69.0% | -28.2% | 2.3% |
Return vs Industry: UUDA underperformed the German Pharmaceuticals industry which returned -27.7% over the past year.
Return vs Market: UUDA underperformed the German Market which returned 2.2% over the past year.
Price Volatility
| UUDA volatility | |
|---|---|
| UUDA Average Weekly Movement | 25.7% |
| Pharmaceuticals Industry Average Movement | 6.6% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.1% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: UUDA's share price has been volatile over the past 3 months.
Volatility Over Time: UUDA's weekly volatility has increased from 20% to 26% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 27 | Gary Phillips | www.syntaratx.com.au |
Syntara Limited operates as a clinical stage drug development company that focuses on blood-related cancers. Its lead product candidate is PXS-5505, which is in phase 2 trial for the bone marrow cancer myelofibrosis, which causes a build-up of scar tissue leading to loss of red and white blood cells and platelets. The company was formerly known as Pharmaxis Ltd and changed its name to Syntara Limited in December 2023.
Syntara Limited Fundamentals Summary
| UUDA fundamental statistics | |
|---|---|
| Market cap | €11.60m |
| Earnings (TTM) | -€6.50m |
| Revenue (TTM) | €11.65m |
1.0x
P/S Ratio-1.8x
P/E RatioIs UUDA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| UUDA income statement (TTM) | |
|---|---|
| Revenue | AU$19.18m |
| Cost of Revenue | AU$11.31m |
| Gross Profit | AU$7.87m |
| Other Expenses | AU$18.56m |
| Earnings | -AU$10.69m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Apr 30, 2024
| Earnings per share (EPS) | -0.009 |
| Gross Margin | 41.03% |
| Net Profit Margin | -55.77% |
| Debt/Equity Ratio | 0% |
How did UUDA perform over the long term?
See historical performance and comparison